![Howard M. Schneider](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Howard M. Schneider
Nessuna posizione attualmente
Profilo
Mr. Howard M.
Schneider is a Director at Aris Industries, Inc. He is on the Board of Directors at Aris Industries, Inc.
Mr. Schneider was previously employed as Independent Director by Novelos Therapeutics, Inc.
He received his undergraduate degree from Harvard University and an MBA from New York University.
Precedenti posizioni note di Howard M. Schneider
Società | Posizione | Fine |
---|---|---|
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Direttore/Membro del Consiglio | 12/02/2014 |
Aris Industries, Inc.
![]() Aris Industries, Inc. Apparel/FootwearConsumer Non-Durables Aris Industries, Inc. engages in licensed trademarks. The firm's licensed products are sold primarily to department and specialty stores and national retail chains. The company was founded in 1947 and is headquartered in New York, NY. | Direttore/Membro del Consiglio | - |
Formazione di Howard M. Schneider
Harvard University | Undergraduate Degree |
New York University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Aris Industries, Inc.
![]() Aris Industries, Inc. Apparel/FootwearConsumer Non-Durables Aris Industries, Inc. engages in licensed trademarks. The firm's licensed products are sold primarily to department and specialty stores and national retail chains. The company was founded in 1947 and is headquartered in New York, NY. | Consumer Non-Durables |
Novelos Therapeutics, Inc.
![]() Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Health Technology |
- Borsa valori
- Insiders
- Howard M. Schneider